eligibility_summary
Adults ≥18 with FIGO III–IV epithelial ovarian/fallopian tube/primary peritoneal cancer (high-grade serous/endometrioid/clear cell or mixed ≥50%), post-cytoreductive surgery and a single platinum chemo course (5–9 cycles) finished 4–12 wks prior, germline/somatic testing without BRCA1/2 mutation, ECOG 0–2, adequate organ function, consent/specimens/follow-up. Exclude: active disease, pregnancy, recent therapy/RT, BRCA+, major comorbidity/immunosuppression, other active malignancy, recent MI/CHF.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06639074 (FAROUT) tests FRαDCs vs placebo in stage III–IV ovarian/fallopian tube/primary peritoneal cancer after surgery and platinum chemo. FRαDCs: autologous cellular immunotherapy (dendritic-cell vaccine) generated from patient leukapheresis, DCs are loaded with multi-epitope folate receptor‑alpha (FRα) antigens and given intradermally. Mechanism: activated DCs present FRα peptides via MHC I/II to prime FRα‑specific CD8+ cytotoxic and CD4+ helper T cells and induce antibodies, enabling killing of FRα‑overexpressing tumor cells and potential epitope spreading. Some patients receive Td/Tdap (inactivated toxoid vaccine) as preconditioning to enhance DC activation/migration. Targets: dendritic cells and T cells in draining nodes, tumor cells expressing FRα, pathways include antigen presentation, TCR signaling, and cytotoxic effector responses. Placebo ID serves as control.